June 12 – 17, 2022
In this presentation, we will discuss recent biocompatibility data obtained using our gamma stable fluoropolymer platform and its advantage in a modern manufacturing environment for the handling of almost any biological fluids.
Single-use, disposable solutions are now widely accepted as gold standard in the biopharmaceutical industry covering every single steps of the drug manufacture process. From early-stage small scale R&D project, upstream production with several thousand-liters bioreactors, downstream process, API formulation up to critical fill & finish and transport applications, the industry is taking a shift with a significant breakthrough reported in 2021: the largest GMP facility in the world using single-use (from 200L to 4,000 L) bioreactors has been publicly announced this year with a global single-use bioreactor workforce of over 150,000 L (with extension plans for 2024 to expand its use of disposable bioreactors to over 430,000 L).
Please click Download on the upper right corner to see the full abstract.
Julien Muzard, Muhammad Siddiqui, and Ross Acucena, "Biomanufacturing using single use systems: Case study of fluoropolymer material" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/93